The eye and thyroid disease

Ajay Kuriyan, Richard P. Phipps, Steven E. Feldon

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Purpose of review: The pathophysiology and optimal management of thyroid eye disease (TED) have not yet been elucidated. Recent studies have increased our knowledge of the disease process and different diagnostic and therapeutic options. This review highlights the recent progress in TED research and identifies areas requiring further advancements. Recent findings The pathophysiology of TED likely involves genetic and environmental factors, which may potentiate cellular and humoral-mediated inflammation within the orbit. Despite progress in TED research, a target antigen has not been established with certainty. New diagnostic methods and questionnaires are being developed that potentially provide information regarding inflammatory activity of TED. Corticosteroids alone or in combination with orbital radiation may be effective in improving TED symptoms. New immunomodulating therapies may also have a role TED management. Surgery is highly effective for treatment of TED-induced optic nerve compression and for managing the chronic soft tissue changes of TED. Summary A unifying hypothesis of TED pathophysiology is elusive. Further bench research into the autoimmune process is needed. In addition, large, prospective, randomized clinical trials based on the inflammatory activity of disease, while difficult to design, are essential to develop a consensus regarding the proper timing and use of anti-inflammatory medications.

Original languageEnglish (US)
Pages (from-to)499-506
Number of pages8
JournalCurrent Opinion in Ophthalmology
Volume19
Issue number6
DOIs
StatePublished - Nov 2008
Externally publishedYes

Fingerprint

Eye Diseases
Thyroid Diseases
Research
Orbit
Optic Nerve
Disease Management
Adrenal Cortex Hormones
Anti-Inflammatory Agents
Randomized Controlled Trials
Radiation
Inflammation
Antigens

Keywords

  • Graves' disease
  • Graves' ophthalmopathy
  • Graves' orbitopathy
  • Thyroid eye disease
  • Thyroid-associated ophthalmopathy

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Kuriyan, A., Phipps, R. P., & Feldon, S. E. (2008). The eye and thyroid disease. Current Opinion in Ophthalmology, 19(6), 499-506. https://doi.org/10.1097/ICU.0b013e3283131557

The eye and thyroid disease. / Kuriyan, Ajay; Phipps, Richard P.; Feldon, Steven E.

In: Current Opinion in Ophthalmology, Vol. 19, No. 6, 11.2008, p. 499-506.

Research output: Contribution to journalArticle

Kuriyan, A, Phipps, RP & Feldon, SE 2008, 'The eye and thyroid disease', Current Opinion in Ophthalmology, vol. 19, no. 6, pp. 499-506. https://doi.org/10.1097/ICU.0b013e3283131557
Kuriyan, Ajay ; Phipps, Richard P. ; Feldon, Steven E. / The eye and thyroid disease. In: Current Opinion in Ophthalmology. 2008 ; Vol. 19, No. 6. pp. 499-506.
@article{4f03d3ab661844049cc4c5d2b3269201,
title = "The eye and thyroid disease",
abstract = "Purpose of review: The pathophysiology and optimal management of thyroid eye disease (TED) have not yet been elucidated. Recent studies have increased our knowledge of the disease process and different diagnostic and therapeutic options. This review highlights the recent progress in TED research and identifies areas requiring further advancements. Recent findings The pathophysiology of TED likely involves genetic and environmental factors, which may potentiate cellular and humoral-mediated inflammation within the orbit. Despite progress in TED research, a target antigen has not been established with certainty. New diagnostic methods and questionnaires are being developed that potentially provide information regarding inflammatory activity of TED. Corticosteroids alone or in combination with orbital radiation may be effective in improving TED symptoms. New immunomodulating therapies may also have a role TED management. Surgery is highly effective for treatment of TED-induced optic nerve compression and for managing the chronic soft tissue changes of TED. Summary A unifying hypothesis of TED pathophysiology is elusive. Further bench research into the autoimmune process is needed. In addition, large, prospective, randomized clinical trials based on the inflammatory activity of disease, while difficult to design, are essential to develop a consensus regarding the proper timing and use of anti-inflammatory medications.",
keywords = "Graves' disease, Graves' ophthalmopathy, Graves' orbitopathy, Thyroid eye disease, Thyroid-associated ophthalmopathy",
author = "Ajay Kuriyan and Phipps, {Richard P.} and Feldon, {Steven E.}",
year = "2008",
month = "11",
doi = "10.1097/ICU.0b013e3283131557",
language = "English (US)",
volume = "19",
pages = "499--506",
journal = "Current Opinion in Ophthalmology",
issn = "1040-8738",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - The eye and thyroid disease

AU - Kuriyan, Ajay

AU - Phipps, Richard P.

AU - Feldon, Steven E.

PY - 2008/11

Y1 - 2008/11

N2 - Purpose of review: The pathophysiology and optimal management of thyroid eye disease (TED) have not yet been elucidated. Recent studies have increased our knowledge of the disease process and different diagnostic and therapeutic options. This review highlights the recent progress in TED research and identifies areas requiring further advancements. Recent findings The pathophysiology of TED likely involves genetic and environmental factors, which may potentiate cellular and humoral-mediated inflammation within the orbit. Despite progress in TED research, a target antigen has not been established with certainty. New diagnostic methods and questionnaires are being developed that potentially provide information regarding inflammatory activity of TED. Corticosteroids alone or in combination with orbital radiation may be effective in improving TED symptoms. New immunomodulating therapies may also have a role TED management. Surgery is highly effective for treatment of TED-induced optic nerve compression and for managing the chronic soft tissue changes of TED. Summary A unifying hypothesis of TED pathophysiology is elusive. Further bench research into the autoimmune process is needed. In addition, large, prospective, randomized clinical trials based on the inflammatory activity of disease, while difficult to design, are essential to develop a consensus regarding the proper timing and use of anti-inflammatory medications.

AB - Purpose of review: The pathophysiology and optimal management of thyroid eye disease (TED) have not yet been elucidated. Recent studies have increased our knowledge of the disease process and different diagnostic and therapeutic options. This review highlights the recent progress in TED research and identifies areas requiring further advancements. Recent findings The pathophysiology of TED likely involves genetic and environmental factors, which may potentiate cellular and humoral-mediated inflammation within the orbit. Despite progress in TED research, a target antigen has not been established with certainty. New diagnostic methods and questionnaires are being developed that potentially provide information regarding inflammatory activity of TED. Corticosteroids alone or in combination with orbital radiation may be effective in improving TED symptoms. New immunomodulating therapies may also have a role TED management. Surgery is highly effective for treatment of TED-induced optic nerve compression and for managing the chronic soft tissue changes of TED. Summary A unifying hypothesis of TED pathophysiology is elusive. Further bench research into the autoimmune process is needed. In addition, large, prospective, randomized clinical trials based on the inflammatory activity of disease, while difficult to design, are essential to develop a consensus regarding the proper timing and use of anti-inflammatory medications.

KW - Graves' disease

KW - Graves' ophthalmopathy

KW - Graves' orbitopathy

KW - Thyroid eye disease

KW - Thyroid-associated ophthalmopathy

UR - http://www.scopus.com/inward/record.url?scp=56249113832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56249113832&partnerID=8YFLogxK

U2 - 10.1097/ICU.0b013e3283131557

DO - 10.1097/ICU.0b013e3283131557

M3 - Article

C2 - 18854695

AN - SCOPUS:56249113832

VL - 19

SP - 499

EP - 506

JO - Current Opinion in Ophthalmology

JF - Current Opinion in Ophthalmology

SN - 1040-8738

IS - 6

ER -